COSCIENS Biopharma Inc.
AEZS
Get informed when a big investor buys or sells
+ FollowMarket Cap$17.51M
Close$
$3.61
36.9% downside
Current Fair Value
36.9% downsideOvervalued by 36.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $17.51 Million |
|---|---|
| Enterprise Value | $-1,794,133.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.65 |
| Beta | 2.26 |
| Outstanding Shares | 2,220,303 |
Return
| Return on Equity | -65.14% |
|---|---|
| Return on Assets | -34.14% |
| Return on Invested Capital | -51.91% |
Valuation & Multiples
| P/E Ratio | -0.89 |
|---|---|
| PEG | 2.04 |
| Price to Sales | 5.72 |
| Price to Book Ratio | 0.52 |
| Enterprise Value to Revenue | -0.73 |
| Enterprise Value to EBIT | 0.09 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -4.74 |
| Debt to Equity | 0.32 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Aeterna Zentaris Inc.
CEO: Klaus Paulini Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company's lead product, macimorelin, is the first and only U.S. FDA and European Commission approved ora...